BofA/Merrill analyst Jay Cohen upgraded Marsh & McLennan (MMC) to Buy citing its better positioning to tax and healthcare exchanges following the election versus Towers Watson (WLTW), which was downgraded to Neutral. The analyst expects Marsh & McLennan to benefit more from tax reform and an improving fundamental backdrop and raised its price target to $75 from $72.

RBC Capital raised the firm's price target on Marsh McLennan to $210 from $208 and keeps a Sector Perform rating on the shares after its Q1 earnings beat. The company's organic growth rate has picked up over the past few quarters, and the solid top-line momentum in the business should remain intact during 2024 with some additional M&A opportunities, the analyst tells investors in a research note. The margin expansion pace for Q1 slowed relative to the recent quarters, but the management expects the margin pace to be higher in the second half of 2024, RBC added.